PainReform (PRFX) Prices 301K Share Offering at $9/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St set to slip as US-Iran tensions cloud start to second half
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil falls as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
July 12, 2023 9:05 AM EDTTEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for the purchase and sale of 301,230 of the Companys ordinary shares (or pre-funded warrants in lieu thereof),... More
